Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Chief Financial Officer | December 26, 2025 | December 30, 2025 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Principal Accounting Officer | June 14, 2017 | June 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date December 26, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,834 |
Reported balance
After 2025-12-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-26 · Sale · Disposed 77,000 · Balance 131,834 F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
MERRIMACK PHARMACEUTICALS INC
Report date June 14, 2017 · Filed June 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2027-06-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-06-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This option vests as to 1/6th of the total number of shares granted on 9/30/17 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 3/30/20. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 1/6th of the total number of shares granted on 9/30/17 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 3/30/20.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2025 Filed Dec 30, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | SaleCommon Stock | 77,000 | $38.68 | $2,978,360.00 |
DisclosureSEC source: 0001193125-25-337051 · ownership.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,834 F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001193125-25-326771 · ownership.xml · derivative · entry 4 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-12-17 F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | Tax withholdingCommon Stock | 145,007 | $39.45 | $5,720,526.15 |
DisclosureSEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 3 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,834 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 2 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,841 F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,841 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 22:03 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0000950170-25-009271 · ownership.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-007410 · ownership.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 20:50 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0000899243-23-005137 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 22:47 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $4.94 Strike: $7.60 | $1,112,220.00 |
DisclosureSEC source: 0000899243-22-003475 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 00:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | SaleCommon Stock | 17,813 | $8.86 | $157,823.18 |
DisclosureSEC source: 0000899243-21-017261 · doc4.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,841 F1 · security: The shares were sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units previously granted to the Reporting Person. F2 · price: The price reported in Column 4 was the weighted-average sale price of the shares. The shares were sold in multiple transactions at prices ranging from $8.80 to $8.90. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the range set forth herein. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:56 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 524 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008812 · doc4.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,654 F1 · security: Reflects shares of common stock issued to the Reporting Person in accordance with the terms of the Contingent Value Rights distributed to certain stockholders pursuant to the Contingent Value Rights Agreement on July 6, 2020. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:17 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 270,746 | $0.00 Strike: $10.17 | $0.00 |
DisclosureSEC source: 0000899243-21-006402 · doc4.xml · derivative · entry 2 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,746 Underlying: Common Stock · 270,746 shares Expires 2031-02-10 F2 · derivative.exercise_date: This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:17 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 111,300 | $0.00 Strike: $10.17 | $0.00 |
DisclosureSEC source: 0000899243-21-006402 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,300 Underlying: Common Stock · 111,300 shares Expires 2031-02-10 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| December 01, 2020 Filed Dec 7, 2020 19:41 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 1,748 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032853 · doc4.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748 F1 · security: Reflects shares of common stock issued to the Reporting Person in accordance with the terms of the Contingent Value Rights distributed to certain stockholders pursuant to the Contingent Value Rights Agreement on July 6, 2020. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 695,700 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-20-054904 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,700 Underlying: Common Stock · 695,700 shares Expires 2030-10-12 F1 · derivative.exercise_date: This stock option shall vest as follows: 25% on the first anniversary of the date of grant then in equal monthly installments over 36 months. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:40 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionRestricted Stock Units · Derivative | 109,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041824 · doc4.xml · derivative · entry 3 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of UMRX common stock. F3 · derivative.exercise_date: On July 6, 2020, all outstanding RSUs of the Issuer vested in full. F3 · derivative.expiration_date: On July 6, 2020, all outstanding RSUs of the Issuer vested in full. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:40 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Tax withholdingCommon Stock | 31,873 | $2.20 | $70,120.60 |
DisclosureSEC source: 0001209191-20-041824 · doc4.xml · nonDerivative · entry 2 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,586 F2 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 23:40 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 109,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-041824 · doc4.xml · nonDerivative · entry 1 Green John L. · CIK 0001709773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of UMRX common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:53 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option · Derivative | 64,400 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-009287 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,400 Underlying: Common Stock · 64,400 shares Expires 2030-02-11 F1 · derivative.exercise_date: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 01:51 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantRestricted Stock Units · Derivative | 109,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057693 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,459 Underlying: Common Stock · 109,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UMRX common stock. F2 · derivative.exercise_date: The restricted stock units shall vest 25% on November 19, 2020, and then in equal monthly installments thereafter for the remaining 12 months, subject to the Reporting Person's continuous service with the Issuer. F2 · derivative.expiration_date: The restricted stock units shall vest 25% on November 19, 2020, and then in equal monthly installments thereafter for the remaining 12 months, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 20:32 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 16,814 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-19-026221 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,814 Underlying: Common Stock · 16,814 shares Expires 2029-04-24 F1 · derivative.exercise_date: 25% of the shares vest on April 24, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 21:08 UTC Amendment | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 21,017 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-025600 · doc4a.xml · derivative · entry 1 Green John L. · CIK 0001709773 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,017 Underlying: Common Stock · 21,017 shares Expires 2029-04-19 F1 · derivative.exercise_date: 25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| March 01, 2019 Filed Apr 11, 2019 20:34 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 21,017 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-19-024366 · doc4.xml · derivative · entry 1 Green John L. · CIK 0001709773 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,017 Underlying: Common Stock · 21,017 shares Expires 2029-03-01 F1 · derivative.exercise_date: 25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.